IMO-001: Solid tumors
A small-molecule trispecific program designed to engage multiple targets at once in solid tumors.
Program Overview
Scientific Rationale
Beyond single-target immunotherapy
Many solid tumors evade single-target immunotherapies by relying on redundant escape mechanisms. Engaging several targets simultaneously may overcome that redundancy.
A trispecific small molecule
This program pursues a small-molecule approach designed to act on three targets at once — combining the multi-target reach usually associated with biologics with the manufacturing and delivery advantages of small molecules.
Our Approach
AI-guided discovery
Omic used its platform to search for chemical matter capable of coordinated multi-target engagement, with digital patient models prioritizing candidates predicted to be active across tumor subtypes.
Where it stands
The program is in lead optimization. The specific targets remain undisclosed.
Program details, including specific molecular targets, are disclosed selectively under confidentiality as part of partnership and licensing discussions.
Interested in Licensing IMO-001?
Contact us to discuss licensing opportunities and partnership terms